156 related articles for article (PubMed ID: 28687529)
21. Production of bioactive lysophosphatidic acid by lysophospholipase D in hen egg white.
Morishige J; Touchika K; Tanaka T; Satouchi K; Fukuzawa K; Tokumura A
Biochim Biophys Acta; 2007 Apr; 1771(4):491-9. PubMed ID: 17321793
[TBL] [Abstract][Full Text] [Related]
22. Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe.
Kawaguchi M; Okabe T; Okudaira S; Nishimasu H; Ishitani R; Kojima H; Nureki O; Aoki J; Nagano T
ACS Chem Biol; 2013 Aug; 8(8):1713-21. PubMed ID: 23688339
[TBL] [Abstract][Full Text] [Related]
23. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.
Saunders LP; Ouellette A; Bandle R; Chang WC; Zhou H; Misra RN; De La Cruz EM; Braddock DT
Mol Cancer Ther; 2008 Oct; 7(10):3352-62. PubMed ID: 18852138
[TBL] [Abstract][Full Text] [Related]
24. Suppression of metastasis of intravenously-inoculated B16/F10 melanoma cells by the novel ginseng-derived ingredient, gintonin: involvement of autotaxin inhibition.
Hwang SH; Lee BH; Kim HJ; Cho HJ; Shin HC; Im KS; Choi SH; Shin TJ; Lee SM; Nam SW; Kim HC; Rhim H; Nah SY
Int J Oncol; 2013 Jan; 42(1):317-26. PubMed ID: 23174888
[TBL] [Abstract][Full Text] [Related]
25. alpha- and beta-substituted phosphonate analogs of LPA as autotaxin inhibitors.
Cui P; McCalmont WF; Tomsig JL; Lynch KR; Macdonald TL
Bioorg Med Chem; 2008 Mar; 16(5):2212-25. PubMed ID: 18082408
[TBL] [Abstract][Full Text] [Related]
26. Virtual screening approaches for the identification of non-lipid autotaxin inhibitors.
Parrill AL; Echols U; Nguyen T; Pham TC; Hoeglund A; Baker DL
Bioorg Med Chem; 2008 Feb; 16(4):1784-95. PubMed ID: 18036821
[TBL] [Abstract][Full Text] [Related]
27. Optimization of a pipemidic acid autotaxin inhibitor.
Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
[TBL] [Abstract][Full Text] [Related]
28. Structural basis for specific inhibition of Autotaxin by a DNA aptamer.
Kato K; Ikeda H; Miyakawa S; Futakawa S; Nonaka Y; Fujiwara M; Okudaira S; Kano K; Aoki J; Morita J; Ishitani R; Nishimasu H; Nakamura Y; Nureki O
Nat Struct Mol Biol; 2016 May; 23(5):395-401. PubMed ID: 27043297
[TBL] [Abstract][Full Text] [Related]
29. Computer Aided Drug Design Approaches for Identification of Novel Autotaxin (ATX) Inhibitors.
Vrontaki E; Melagraki G; Kaffe E; Mavromoustakos T; Kokotos G; Aidinis V; Afantitis A
Curr Med Chem; 2016; 23(17):1708-24. PubMed ID: 26997151
[TBL] [Abstract][Full Text] [Related]
30. Steroid binding to Autotaxin links bile salts and lysophosphatidic acid signalling.
Keune WJ; Hausmann J; Bolier R; Tolenaars D; Kremer A; Heidebrecht T; Joosten RP; Sunkara M; Morris AJ; Matas-Rico E; Moolenaar WH; Oude Elferink RP; Perrakis A
Nat Commun; 2016 Apr; 7():11248. PubMed ID: 27075612
[TBL] [Abstract][Full Text] [Related]
31. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
[TBL] [Abstract][Full Text] [Related]
32. A 3D view of autotaxin.
Nishimasu H; Ishitani R; Aoki J; Nureki O
Trends Pharmacol Sci; 2012 Mar; 33(3):138-45. PubMed ID: 22277299
[TBL] [Abstract][Full Text] [Related]
33. An updated patent review of autotaxin inhibitors (2017-present).
Tan Z; Lei H; Guo M; Chen Y; Zhai X
Expert Opin Ther Pat; 2021 May; 31(5):421-434. PubMed ID: 33342311
[TBL] [Abstract][Full Text] [Related]
34. Molecular modelling guided design, synthesis and QSAR analysis of new small molecule non-lipid autotaxin inhibitors.
Banerjee S; Norman DD; Deng S; Fakayode SO; Lee SC; Parrill AL; Li W; Miller DD; Tigyi GJ
Bioorg Chem; 2020 Oct; 103():104188. PubMed ID: 32890995
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836
[TBL] [Abstract][Full Text] [Related]
36. Development and therapeutic potential of autotaxin small molecule inhibitors: From bench to advanced clinical trials.
Matralis AN; Afantitis A; Aidinis V
Med Res Rev; 2019 May; 39(3):976-1013. PubMed ID: 30462853
[TBL] [Abstract][Full Text] [Related]
37. Autotaxin--an LPA producing enzyme with diverse functions.
Nakanaga K; Hama K; Aoki J
J Biochem; 2010 Jul; 148(1):13-24. PubMed ID: 20495010
[TBL] [Abstract][Full Text] [Related]
38. Increased Autotaxin Levels in Severe COVID-19, Correlating with IL-6 Levels, Endothelial Dysfunction Biomarkers, and Impaired Functions of Dendritic Cells.
Nikitopoulou I; Fanidis D; Ntatsoulis K; Moulos P; Mpekoulis G; Evangelidou M; Vassiliou AG; Dimakopoulou V; Jahaj E; Tsipilis S; Orfanos SE; Dimopoulou I; Angelakis E; Akinosoglou K; Vassilaki N; Tzouvelekis A; Kotanidou A; Aidinis V
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576169
[TBL] [Abstract][Full Text] [Related]
39. Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors.
Magkrioti C; Kaffe E; Stylianaki EA; Sidahmet C; Melagraki G; Afantitis A; Matralis AN; Aidinis V
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977539
[TBL] [Abstract][Full Text] [Related]
40. Structure-based discovery of (S)-2-amino-6-(4-fluorobenzyl)-5,6,11,11a-tetrahydro-1H-imidazo[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione as low nanomolar, orally bioavailable autotaxin inhibitor.
Roy A; Sarkar T; Datta S; Maiti A; Chakrabarti M; Mondal T; Mondal C; Banerjee A; Roy S; Mukherjee S; Muley P; Chakraborty S; Banerjee M; Kundu M; Roy KK
Chem Biol Drug Des; 2022 Mar; 99(3):496-503. PubMed ID: 34951520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
